Avalo Therapeutics Inc. (AVTX)
NASDAQ · Healthcare
Avalo Therapeutics Inc. EBITDA 2015–2025
Avalo Therapeutics Inc. annual/quarterly ebitda history and growth rate from 2015 to 2024. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Avalo Therapeutics Inc. ebitda for the quarter ending March 31, 2024 was -32.7 M, a 273.71% increase year-over-year.
- Avalo Therapeutics Inc. ebitda for the twelve months ending March 31, 2024 was -92.4 M, a 133.99% increase year-over-year.
- Avalo Therapeutics Inc. annual ebitda for 2025 was -72.6 M, a 6.20% increase from 2024.
- Avalo Therapeutics Inc. annual ebitda for 2024 was -68.3 M, a 151.33% increase from 2023.
- Avalo Therapeutics Inc. annual ebitda for 2023 was -27.2 M, a 27.05% decrease from 2022.
- Avalo Therapeutics Inc. annual ebitda for 2022 was -37.3 M.
EBITDA
TRAILING 12 MONTHS · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Avalo Therapeutics Inc. EBITDA — FAQ
Avalo Therapeutics Inc. (AVTX) ebitda over the last 11 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see AVTX's ebitda history?
The chart and table above show Avalo Therapeutics Inc.'s ebitda by year and by quarter, including the growth rate.